Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717039 · ClinicalTrials.gov registry record
Pharmacogenomics of Heparin-Induced Thrombocytopenia
A clinical trial of Heparin-induced Thrombocytopenia, sponsored by University of Arizona.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT02717039: Recruiting study of Heparin-induced Thrombocytopenia, sponsored by University of Arizona.
NCT02717039 is a study of Heparin-induced Thrombocytopenia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 125 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02717039, a study of Heparin-induced Thrombocytopenia, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Arizona
- Banner University Medical Center - Tucson - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-03 |
| Est. Completion | 2026-07 |
What NCT02717039 shows while recruiting
NCT02717039 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Heparin-induced Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT02717039 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02717039 about?
NCT02717039 is a clinical study titled "Pharmacogenomics of Heparin-Induced Thrombocytopenia". The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prev...
What is the current status of trial NCT02717039?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2016-03. Estimated completion is 2026-07.
What conditions does trial NCT02717039 study?
This clinical trial studies the following conditions: Heparin-induced Thrombocytopenia.
What interventions are being tested in trial NCT02717039?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02717039?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02717039 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heparin-induced Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
COMPLETED · Phase 1
-
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
- NCT03107520 · 125 participants · Early Phase 1
Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia